Apr 24, 2024 (24/7 Market News via COMTEX) --
DENVER, Colo., Apr 23, 2024 (247marketnews.com)- Palisade Bio, Inc. (Nasdaq:PALI) stated that the Company entered into a strategic collaboration with Strand Life Sciences, aimed at advancing precision medicine for ulcerative colitis (UC) therapy.
Palisade Bio will access Strand Life Sciences's advanced bioinformatics tools vital for understanding complex disease pathways and predicting responses to PDE4 inhibitors.
“Our partnership with Strand Life Sciences signifies a pivotal advancement in our mission to revolutionize UC treatment,” stated Dr. Mitch Jones, CMO at Palisade Bio. “By harnessing the power of bioinformatics and leveraging extensive patient datasets, we are highly optimistic in our ability to deliver personalized therapies that offer new hope to patients living with UC. More immediately, the findings from this collaboration will provide valuable guidance and insight for our lead program, PALI-2108.”
Leveraging data from over ten UC clinical studies, Palisade curated a pipeline of 1600 UC patient samples, including transcriptomics and clinical outcomes, which were analyzed using in-house tools, enables Palisade to identify biomarkers for selecting UC patient responders, utilizing machine learning to develop a precision medicine approach to patient selection.
“We are thrilled to collaborate with Palisade Bio in this transformative endeavor toward advancing precision medicine for ulcerative colitis therapy,” commented Ramesh Hariharan, CEO at Strand Life Sciences. “Our expertise in bioinformatics, machine learning/AI and knowledge curation towards biomarker stratification, combined with Palisade’s extensive patient datasets, holds immense promise in identifying predictive biomarkers and ultimately improving outcomes for UC patients.”
The post Palisade Bio forms Strategic Collaboration with Strand Life Sciences appeared first on 24/7 MarketNews.
COMTEX_451345555/2900/2024-04-24T11:16:24
